(CNTA) Centessa Pharmaceuticals - Ratings and Ratios
Sleep Disorder Drug, Neurodegenerative Drug, Neuropsychiatric Drug, Tumor Therapy
| Risk via 10d forecast | |
|---|---|
| Volatility | 75.0% |
| Value at Risk 5%th | 116% |
| Relative Tail Risk | -5.67% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.91 |
| Alpha | 48.19 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.408 |
| Beta | 1.029 |
| Beta Downside | 1.476 |
| Drawdowns 3y | |
|---|---|
| Max DD | 43.72% |
| Mean DD | 13.64% |
| Median DD | 11.08% |
Description: CNTA Centessa Pharmaceuticals November 10, 2025
Centessa Pharmaceuticals plc (NASDAQ: CNTA) is a UK-based, clinical-stage biotech focused on neuro-sleep and neuro-psychiatric disorders. Its flagship candidate, ORX750, is an oral orexin-2-receptor (OX2R) agonist currently in a Phase 2a trial targeting idiopathic hypersomnia and both types of narcolepsy, conditions that collectively affect an estimated 0.5 % of the adult population in North America and Europe.
Beyond ORX750, the pipeline includes ORX142, a next-generation orexin agonist aimed at broader neurological indications such as excessive daytime sleepiness, attention deficits, and cognitive fatigue, and ORX489, which is being evaluated for neuropsychiatric disorders. The company also markets LockBody, a proprietary antibody platform designed to deliver potent CD3-mediated effector activity directly into the tumor microenvironment, positioning it for potential oncology collaborations.
From a financial perspective, Centessa reported a cash balance of approximately $45 million at the end of Q2 2024, giving it roughly 12-month runway assuming current burn rates (~$3.5 million per month). The biotech sector’s recent 8 % YoY increase in venture capital funding for sleep-disorder therapeutics suggests a favorable capital environment for companies advancing orexin-based pipelines.
Analysts should monitor enrollment velocity in the ORX750 Phase 2a study (target 150 patients) and any interim efficacy readouts, as these data points will materially affect valuation assumptions. For a deeper, data-driven assessment of CNTA’s risk-adjusted upside, consider exploring the quantitative models on ValueRay.
CNTA Stock Overview
| Market Cap in USD | 2,974m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2021-05-28 |
| Return 12m vs S&P 500 | 37.6% |
| Analyst Rating | 4.64 of 5 |
CNTA Dividends
Currently no dividends paidCNTA Growth Ratios
| CAGR 3y | 100.16% |
| CAGR/Max DD Calmar Ratio | 2.29 |
| CAGR/Mean DD Pain Ratio | 7.34 |
| Current Volume | 3530.7k |
| Average Volume | 904.6k |
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income (-242.7m TTM) > 0 and > 6% of Revenue (6% = 957.1k TTM) |
| FCFTA -0.40 (>2.0%) and ΔFCFTA -19.57pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 1746 % (prev 7908 %; Δ -6162 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.40 (>3.0%) and CFO -180.8m > Net Income -242.7m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 10.57 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (134.2m) change vs 12m ago 15.41% (target <= -2.0% for YES) |
| Gross Margin 94.22% (prev 85.95%; Δ 8.26pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 3.02% (prev 1.12%; Δ 1.89pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -32.96 (EBITDA TTM -229.5m / Interest Expense TTM 5.35m) >= 6 (WARN >= 3) |
Altman Z'' -14.30
| (A) 0.62 = (Total Current Assets 307.7m - Total Current Liabilities 29.1m) / Total Assets 448.3m |
| (B) -2.50 = Retained Earnings (Balance) -1.12b / Total Assets 448.3m |
| warn (B) unusual magnitude: -2.50 — check mapping/units |
| (C) -0.33 = EBIT TTM -176.3m / Avg Total Assets 529.0m |
| (D) -7.61 = Book Value of Equity -1.12b / Total Liabilities 146.7m |
| Total Rating: -14.30 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 35.25
| 1. Piotroski 1.0pt = -4.0 |
| 2. FCF Yield -6.62% = -3.31 |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.03 = 2.50 |
| 5. Debt/Ebitda 0.19 = 2.47 |
| 6. ROIC - WACC (= -46.12)% = -12.50 |
| 7. RoE -67.68% = -2.50 |
| 8. Rev. Trend 33.44% = 2.51 |
| 9. EPS Trend 1.67% = 0.08 |
What is the price of CNTA shares?
Over the past week, the price has changed by +24.82%, over one month by +23.20%, over three months by +56.52% and over the past year by +57.77%.
Is Centessa Pharmaceuticals a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CNTA is around 28.00 USD . This means that CNTA is currently overvalued and has a potential downside of 1.41%.
Is CNTA a buy, sell or hold?
- Strong Buy: 7
- Buy: 4
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the CNTA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 33.9 | 22.9% |
| Analysts Target Price | 33.9 | 22.9% |
| ValueRay Target Price | 31.6 | 14.4% |
CNTA Fundamental Data Overview November 10, 2025
P/S = 198.2658
P/B = 8.9598
Beta = 1.572
Revenue TTM = 16.0m USD
EBIT TTM = -176.3m USD
EBITDA TTM = -229.5m USD
Long Term Debt = 108.9m USD (from longTermDebt, last fiscal year)
Short Term Debt = 656.0k USD (from shortTermDebt, two quarters ago)
Debt = 7.76m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -43.1m USD (from netDebt column, last quarter)
Enterprise Value = 2.74b USD (2.97b + Debt 7.76m - CCE 246.2m)
Interest Coverage Ratio = -32.96 (Ebit TTM -176.3m / Interest Expense TTM 5.35m)
FCF Yield = -6.62% (FCF TTM -181.2m / Enterprise Value 2.74b)
FCF Margin = -1136 % (FCF TTM -181.2m / Revenue TTM 16.0m)
Net Margin = -1521 % (Net Income TTM -242.7m / Revenue TTM 16.0m)
Gross Margin = 94.22% ((Revenue TTM 16.0m - Cost of Revenue TTM 922.6k) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 6.10 (Enterprise Value 2.74b / Total Assets 448.3m)
Interest Expense / Debt = -37.25% (Interest Expense -2.89m / Debt 7.76m)
Taxrate = -0.30% (negative due to tax credits) (166.0k / -54.7m)
NOPAT = -176.9m (EBIT -176.3m * (1 - -0.30%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 10.57 (Total Current Assets 307.7m / Total Current Liabilities 29.1m)
Debt / Equity = 0.03 (Debt 7.76m / totalStockholderEquity, last quarter 301.6m)
Debt / EBITDA = 0.19 (negative EBITDA) (Net Debt -43.1m / EBITDA -229.5m)
Debt / FCF = 0.24 (negative FCF - burning cash) (Net Debt -43.1m / FCF TTM -181.2m)
Total Stockholder Equity = 358.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -54.14% (Net Income -242.7m / Total Assets 448.3m)
RoE = -67.68% (Net Income TTM -242.7m / Total Stockholder Equity 358.6m)
RoCE = -37.72% (EBIT -176.3m / Capital Employed (Equity 358.6m + L.T.Debt 108.9m))
RoIC = -36.33% (negative operating profit) (NOPAT -176.9m / Invested Capital 486.8m)
WACC = 9.78% (E(2.97b)/V(2.98b) * Re(9.81%) + (debt cost/tax rate unavailable))
Discount Rate = 9.81% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 17.05%
Fair Price DCF = unknown (Cash Flow -181.2m)
EPS Correlation: 1.67 | EPS CAGR: 3.29% | SUE: -0.12 | # QB: 0
Revenue Correlation: 33.44 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
Additional Sources for CNTA Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle